Econazole Nitrate

Neosalus® Products Are Second Relaunch Announced by Resilia in Less Than One Month ATLANTA, May 3, 2023 /PRNewswire/ -- Resilia Pharmaceuticals, Inc. announced today that it has brought Neosalus® Cream and Neosalus® Lotion back to the market. Neosalus® Lotion is a non-steroidal anti-inflammatory prescription product that offers topical treatment for the management of skin disorders, including atopic dermatitis and allergic contact dermatitis. These products had not been available due to supply chain disruptions that occurred as a result of the COVID-19 public health crisis. Resilia Pharmaceuticals Brings Neosalus® Cream and Neosalus® Lotion Back to Market; Follows April 2023 Solace Relaunch Resilia acquired the rights to make, market and sell the Neosalus® products in December 2020. Neosalus® Cream received regulatory clearance from the US FDA in April 2009. Neosalus® Lotion was launched in November 2011. Both Neosalus® Lotion and Neosalus® Cream, use patented Proderm Technology® to help provide skin barrier repair, protection, and hydration1. In addition, the Neosalus® line of products is specially formulated with several key ingredients that can promote healthy skin: dimethicone to help restore the skin barrier and reduce trans-epidermal water loss (TEWL)1,2; glycerin, a humectant to help retain moisture1; and stearic/palmitic acids to produce ceramides, cholesterol, and other free fatty acids in the ratio the skin needs1. All Neosalus® products are non-comedogenic and petrolatum-free and do not contain steroids or alcohol1,3. "We could not be more pleased to restore the supply and bring Neosalus® Cream and Neosalus® Lotion back to patients and prescribers," said Harsha Murthy, Executive Chairman of the Board of Resilia Pharmaceuticals. "Patients and prescribers have been contacting us over the last two years asking when they will be able to get these products. These products will now be available nationwide in pharmacies, clinics and dermatologists' offices where patients, in consultation with their health care providers, can get the relief they need." Murthy continued, "We at Resilia are especially proud that, along with our relaunch of Solace® Eczema Cream that we announced on April 19th of this year, we are demonstrating how to create value for patients and investors by keeping high-quality, reasonably priced therapeutics on the market." Andrew Shales, Chief Executive Officer of Resilia, said "Dermatitis has many causes and appears in several forms. Multiple Neosalus® dosage forms offer convenient options to meet patients' site-specific needs – Neosalus® Cream is often used to treat problem dry skin on the hands, face, and elbows and Neosalus® Lotion is often used for total body coverage, including the face. Patients may particularly like the steroid-free characteristics of Neosalus®1,3. This is something we heard often from prescribers and past patients." Mike Leone, Chief Operating Officer of Resilia, said "In addition to the therapeutic benefits of Neosalus® Cream and Neosalus® Lotion, patients will likely appreciate the cosmetic elegance of Proderm Technology®. Unlike some creams and lotions which tend to leave the skin feeling greasy after application, Neosalus®, a water-lipid based formulation, absorbs quickly, spreads easily, and is non-greasy1. Patients can resume their work and daily activities immediately after applying Neosalus®, thus enhancing compliance and maximizing treatment results. We have shipped Neosalus® so that prescription drug wholesalers can make the products available to their pharmacy, clinic and physician customers." About Resilia Pharmaceuticals™. Resilia Pharmaceuticals, Inc™. is a portfolio company of Peak Pharma Commercial Partners, a New York City-based investment fund dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products (www. peakpharmapartners.com). Headquartered in Atlanta, Georgia, Resilia Pharmaceuticals' prescription product line consists of Recedo® topical gel, the #1 prescribed Rx scar treatment over the past 5 years3; Ecoza® (econazole nitrate) topical foam, 1%; the Neosalus® line, including cream, foam, and lotion formulations for eczema/atopic dermatitis; and Neocera®, a version of Neosalus formulated with ceramides. Santefirm Consumer Healthcare, Inc.™, also headquartered in Atlanta, Georgia, is the Resilia affiliate that sells non-prescription, over-the-counter products. Santefirm currently markets and sells Solace® anti-eczema cream on Amazon. All of Resilia and Santefirm's respective products are marketed and manufactured in the US. To learn more about Resilia Pharmaceuticals, please go to . Citations: Ghadially R, Silvander M. Penetration study results using Proderm Technology foam. Poster presented at: 7th Annual Caribbean Dermatology Symposium; January 15-19, 2008; St Thomas, US Virgin Islands. Zhai H, Brachman F, Pelosi A, et al. A bioengineering study on the efficacy of a skin protectant lotion in preventing SLS-induced dermatitis. Skin Res Technol. 2000:6(2):77-80. Data on file; Atlanta, Georgia. Resilia Pharmaceuticals. 2023 Contact: info@resiliapharmaceuticals.com Phone: 888-998-0770

Formerly Available only by Prescription, Solace® is First of Several Over-the-Counter Products to be Marketed Under Resilia's Santefirm Consumer Healthcare Label ATLANTA, April 19, 2023 /PRNewswire/ -- Resilia Pharmaceuticals, Inc. announced today that it has re-launched Solace® Eczema Cream on Amazon® and restored the supply of this product that had formerly only been available by prescription. Solace is marketed under Resilia's Santefirm Consumer Healthcare, Inc.™ label. Resilia Pharmaceuticals Announces Relaunch of Solace® Eczema Cream on Amazon® Solace® Cream is formulated to help control eczema flares and keep future eczema flares dormant longer by utilizing essential skin building blocks like cholesterol, fatty acids, and ceramides to help reduce the likelihood of environmental triggers causing eczema symptoms; as well as employing palmitamide MEA (PEA), a natural endogenous fatty acid to help relieve itchy, dry skin often associated with eczema. Solace® is available on Amazon® at "We are delighted to be able to bring Solace® back to the market," said Harsha Murthy, Executive Chairman of the Board of Directors at Resilia Pharmaceuticals. "We are also pleased that Solace® will be the first of many non-prescription, over-the-counter products that Santefirm will be launching in the coming months and years," Mr. Murthy said. "We are committed to meeting patients where they are when they need relief from dermatological conditions, Solace® gives patients a high-quality treatment option at a highly reasonable price and takes advantage of Amazon's world-class fulfillment/delivery channel." Andrew Shales, Chief Executive Officer of Resilia, noted, "Solace® is an ideal complement to our prescription line of dermatology products sold under our Resilia label. We know that patients experience skin conditions in a range of severity, from acute and severe outbreaks to chronic symptoms. Resilia and Santefirm have developed a product portfolio that can help patients at each stage, and we anticipate our additional product offerings will address even more of our patients' needs. Patients in consultation with their physicians/prescribers/health care professionals can now get the type of treatment best suited to their needs." Mike Leone, Chief Operating Officer of Resilia, said "Since acquiring the rights to Solace® in October 2021, the Resilia and Santefirm teams have worked closely with our manufacturing partners to bring this product back to patients suffering with eczema." Leone continued, "We have restored the supply chain to ensure the availability of the product. Moreover, we anticipate that we will undertake new promotional efforts to alert patients to the scientifically supported benefits of Solace® and the ease with which they can get Solace® on Amazon®." About Solace® Cream ( ) Solace® Cream: repairs and restores the skin barrier; keeps eczema in remission up to 48% longer1 reduces average weekly steroid applications by 62%2 improves sleep quality3 About Eczema Eczema symptoms are different for everyone, though in most cases, eczema causes itching and can make skin appear dry, red, rough, or swollen. This itching can be mild or severe, resulting in inflamed and even damaged skin. While the specific cause of eczema remains unknown, healthcare professionals believe the disease often occurs from a combination of factors. Professionals believe that environmental irritants, like detergents, allergens, and bacteria, as well as shifts in temperature, types of foods, stress, or hormones, can cause an eczema flare-up. About Resilia Pharmaceuticals™ and Santefirm Consumer Healthcare, Inc™. Resilia Pharmaceuticals, Inc™. is a portfolio company of Peak Pharma Commercial Partners, a New York City-based investment fund dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products (www. peakpharmapartners.com). Headquartered in Atlanta, Georgia, Resilia Pharmaceuticals' prescription product line consists of Recedo® topical gel, the #1 prescribed Rx scar treatment over the past 5 years3; Ecoza® (econazole nitrate) topical foam, 1%; the Neosalus® line, including cream, foam, and lotion formulations for eczema/atopic dermatitis; and Neocera®, a version of Neosalus formulated with ceramides. Santefirm Consumer Healthcare, Inc™., also headquartered in Atlanta, Georgia, is the Resilia affiliate that sells non-prescription, over-the-counter products. All of Resilia and Santefirm's respective products are marketed and manufactured in the US. To learn more about Resilia Pharmaceuticals, Santefirm and their products, please go to and Citations: Kircik L. A Nonsteroidal Lamellar Matrix Cream Containing Palmyitoyethanolamide for the Treatment of Atopic Dermatitis. J Drugs Dermatol. 2010; 4: 334. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant Treatment of Atopic Eczema: Assessment of an Emollient Containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008; 22(1): 73-82. Symphony Health. Defined Scar Treatment Market TRxs, Jan 2017-Aug 2021 Contact: info@resiliapharmaceuticals.com Phone: 888-998-0770